Premium
A BCR–JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia
Author(s) -
Griesinger Frank,
Hennig Heike,
Hillmer Frauke,
Podleschny Martina,
Steffens Rainer,
Pies Andreas,
Wörmann Bernhard,
Haase Detlef,
Bohlander Stefan K.
Publication year - 2005
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/gcc.20235
Subject(s) - breakpoint cluster region , fusion gene , fusion protein , myeloid leukemia , chromosomal translocation , fluorescence in situ hybridization , gene , tyrosine kinase , breakpoint , cancer research , biology , imatinib , abl , microbiology and biotechnology , genetics , chromosome , receptor , recombinant dna
Chronic myeloid leukemia (CML) is characterized by the presence of a t(9;22)(q34;q11.2), which leads to the well‐known BCR–ABL1 fusion protein. We describe a patient who was diagnosed clinically with a typical CML but on cytogenetic analysis was found to have a t(9;22)(p24;q11.2). Chromosomal fluorescence in situ hybridization showed that the BCR gene locus spanned the breakpoint at band 22q11.2 but that the ABL1 gene was not rearranged. By means of a candidate gene approach, the JAK2 gene, at 9p24, was identified as the fusion partner of BCR in this case. The BCR–JAK2 fusion protein contains the coiled‐coil dimerization domain of BCR and the protein tyrosine kinase domain (JH1) of JAK2. The patient's disease did not respond to Imatinib, and this unresponsiveness was most likely a result of the BCR–JAK2 fusion protein. © 2005 Wiley‐Liss, Inc.